Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on February 7, 2022, by Denali Therapeutics Inc. The filing reports on corporate governance events that occurred on February 3, 2022, specifically the appointment of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and board appointments.
Material Changes
The primary material change is the appointment of Erik Harris to the Board of Directors and the Audit Committee. No financial performance changes or operational shifts are reported in this document.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of Mr. Harris's compensatory arrangements:
- Cash Compensation: $45,000 annual base for Board service plus $10,000 annual additional compensation for Audit Committee service, payable quarterly in arrears.
- Initial Equity Awards: An initial grant of stock options and Restricted Stock Units (RSUs) with an aggregate company-assessed value of approximately $700,000.
- Equity Split: 60% of the initial award value is in stock options; 40% is in RSUs.
- Vesting Schedule:
- Options: 25% vests on the one-year anniversary; the remainder vests monthly (1/48th) thereafter.
- RSUs: Vests over four years, with 25% vesting on each anniversary.
- Future Awards: Eligible for annual awards valued at approximately $400,000 (60% options, 40% RSUs) vesting fully within one year or prior to the next annual meeting.
The filing states there are no undisclosed arrangements or transactions required under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of shares underlying the $700,000 initial equity grant based on the stock price on February 3, 2022.
- Confirm the impact of the new director on the composition of the Audit Committee.
- Review the Company's 2017 Equity Incentive Plan to understand the specific terms governing the granted options and RSUs.
- Check subsequent filings for the actual vesting dates and any acceleration clauses triggered by corporate events.